ACAT2 and NPC1L1 — Drug Target

All drugs that target ACAT2 and NPC1L1 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Cholesterol absorption inhibitor combination

Phase 3 pipeline (1)

• Lapaquistat acetate and ezetimibe · Takeda · Cholesterol absorption inhibitor combination · Cardiovascular
  Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while ezetimibe blocks NPC1L1 to further decrease cholesterol uptake, together lowering LDL cholesterol.